Galderma sues Lupin over Oracea generic

Galderma Laboratories has sued Lupin Pharmaceuticals alleging that it plans to manufacture and sell a generic version of Oracea (doxycycline) prior to the expiration of key patents.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Lupin and Sun settle Bromsite patent suit after ruling

10 February 2022 Sun Pharmaceuticals and Lupin Pharmaceuticals have decided to settle a patent suit related to Sun’s Bromsite eye drops, invalidating an opinion handed down by the US District Court for the District of New Jersey in September.

Americas

Fed Circuit hands win to Galderma in Teva suit

30 January 2020 The US Court of Appeals for the Federal Circuit has revived patent infringement litigation brought against Teva by dermatological company Galderma, a former subsidiary of Nestlé Skin Health.

Americas

Galderma fends off Dr Reddy IPR claims

17 February 2016 Galderma Laboratories has successfully avoided three inter partes review petitions being instituted against a patent covering its Oracea (doxycycline, USP) drug, used to treat skin condition rosacea.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Galderma sues Lupin over Oracea generic

More on this story

Editor's picks

Editor's picks

More features